By Fineline Cube 
On September 12, 2025, Jingze Biopharmaceutical (Hefei) Co., Ltd., based in China, and a subsidiary of China Medical System Holdings (CMS, HKG: 0867; SGX: 8A8), announced a strategic cooperation agreement. The collaboration centers on the commercialization of multiple core products in the fields of assisted reproduction and ophthalmology, with the goal of expanding into domestic and international markets.
Core Products and Market Potential
The partnership will focus on three key products from Jingze Bio: JZB30 and JZB33 for assisted reproduction, and JZB05 for ophthalmology. These products address significant unmet clinical needs and specialized treatment segments, offering substantial market potential.
International Expansion
Beyond the domestic market, Jingze Bio has signed a License and Supply Agreement with Rxilient Medical Pte. Ltd., a subsidiary of CMS, granting Rxilient the rights to JZB30, JZB33, and JZB05 in regions including Southeast Asia, Australia, New Zealand, South Korea, the Middle East, and Africa.
Regulatory Preparation
Both parties have initiated preparations for the JZB30 project’s application materials for the Singapore market.-Fineline Info & Tech